Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
 |
Voice of America - July 26, 2007
Véronique LaCapra
Washington, DC
In the United States, people tend to think of measles as a rare childhood illness, easily preventable through routine vaccination. But in much of the world, large numbers of children still die from this highly contagious disease. In areas where many infants are born HIV-positive, the risk is even worse. But a new study suggests that repeated measles vaccinations may help.
Measles killed more than 450,000 people in 2004, according to the U.S. Centers for Disease Control. More than half of those deaths were in sub-Saharan Africa, a region also hard hit by HIV and AIDS.
William Moss is an epidemiologist at the Johns Hopkins Bloomberg School of Public Health. He and his colleagues have been studying the effectiveness of measles vaccines given to children in Lusaka, Zambia. In their study, 441 children were vaccinated, including 66 who were infected with HIV.
"The children were given measles vaccine at nine months of age," Moss explains, "and then asked to return either one or three months after vaccination for evaluation and for a blood test." The test measured the concentration of protective antibodies in the children's blood following vaccination.
Previous studies had suggested that measles vaccination might not be effective in HIV-infected children. Surprisingly, Moss found that within six months of vaccination, almost as many HIV-infected children developed protective levels of measles antibodies, as did those who were HIV-negative.
He and his colleagues then had the children return for follow-up tests at two and three years of age. "As we followed these children over time, the protective [measles] antibody levels in the HIV-infected children declined."
As would be expected, the mortality rate of the HIV-infected group was very high. In fact, over the course of the study, 28 of the HIV-positive children died.
But Moss found that of those who survived, only about half retained protective antibody levels, compared to about 90 percent of the uninfected children.
In 2003, Zambia conducted a highly successful measles prevention campaign, vaccinating an estimated 97 percent of children between six months and 14 years of age. For Moss, the campaign provided an additional opportunity, by allowing him to analyze the response to re-vaccination of a small number of the HIV-infected children.
Moss found that about 90 percent of those children had protective antibody levels, following the second vaccination. These results suggest that "in the short term, re-vaccination was able to protect these children," says Moss.
The World Health Organization recommends that all children be vaccinated twice to protect them from measles infection. Moss's research indicates that repeated vaccinations may be especially critical in countries with high rates of HIV-infection.
Access to HIV medications in Zambia has dramatically increased since Moss and his colleagues began their research. They plan to start a new study in October, to examine the effects of measles vaccination in children who are receiving antiretroviral therapy.
The results of their current study will be published in the August 1 in The Journal of Infectious Diseases. Their paper is also available online.
070726
VA070722
Copyright © 2007 - Voice of America. You are welcome to use any material that is published by voanews.com, or you may link to any of the web pages that Voice of America has published on the internet. There is no need to request further permission. Should you wish to establish a link to any VOA web pages, please send your request to pubaff@ibb.gov. We would appreciate that credit for any use of VOA material be given to voanews.com, Voice of America, or VOA, and we ask that you not abridge or edit any VOA material which you may use.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, John M. Lloyd Foundation, the National Library of Medicine, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .